Moderna
RSV
page 1 of 3
4C
(near RSV)
INDICATION
mRESVIA (Respiratory Syncytial Virus Vaccine) is 
a vaccine indicated for active immunization for 
the prevention of lower respiratory tract disease 
(LRTD) caused by respiratory syncytial virus (RSV) 
in individuals 60 years of age and older and 
individuals 18 through 59 years of age who are at 
increased risk for LRTD caused by RSV.
IMPORTANT SAFETY INFORMATION
Contraindications
Do not administer mRESVIA to individuals 
with a history of severe allergic reaction (e.g., 
anaphylaxis) to any component of mRESVIA.   
Warnings and Precautions
•  Management of Acute Allergic Reactions: 
Appropriate medical treatment must be 
immediately available to manage potential 
anaphylactic reactions following administration 
of mRESVIA.
•  Syncope: Syncope (fainting) may occur in 
association with administration of injectable 
vaccines, including mRESVIA. Procedures should 
be in place to avoid injury from fainting.
•  Altered Immunocompetence: 
Immunocompromised individuals, including 
those receiving immunosuppressive therapy, 
may have a diminished immune response to 
mRESVIA.
CDC recommended1,2
mRESVIA IS READY.
1*
THE ONLY RSV
PROTECTION IN A 
PRE-FILLED SYRINGE
1
Help move patients from RSV at-risk to RSV protected with mRESVIA— 
no reconstitution required.1
*mRESVIA is ready to use once thawed. 
For the prevention of RSV in adults aged 60 years and 
adults aged18 to 59 at increased risk for RSV-LRTD. 

View this content as a flipbook by clicking here.